Latest version of ClearTrial software expands ability of life sciences organizations to accelerate the planning, execution, and outsourcing of clinical trials.
Chicago, IL-May 8, 2008-ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing, announced today that it has released v2.4 of its market-leading ClearTrial clinical trial software, which helps biopharmaceutical companies and clinical research organizations (CROs) more effectively plan, budget, outsource, and optimize the operational design of clinical trials. Officially unveiled at the 2008 Partnerships with CROs conference, v2.4 of the ClearTrial software is now used by some of the largest biopharma organizations in the industry and by five of the top 10 biotech companies.
For the past several years, ClearTrial’s customers in clinical operations, outsourcing, finance, and project management have been drawing on the web-based software’s innovative, easy-to-use design to apply a true activity-based planning approach to:
The latest version of the software provides customers with even greater control and flexibility over their clinical operations planning. Among the key enhancements in ClearTrial v2.4 are support for mixed-monitoring strategies, a customizable milestone payment schedule and cash flow chart for an accurate cash flow status for each month of the study, greater flexibility to set resources and rate per-plan or per-task, and the ability for upload service provider rates into the software.
In addition, v2.4 broadens the already considerable array of clinical, cost, and resources reports available in the software, adding “Resources by Major Task” and “Resources by Department” reports to give planners a detailed and customizable look at resources-and enhancing support for resource forecasting and negotiating how studies will be staffed.
“ClearTrial software continues to lead the market in giving life sciences organizations the planning speed, flexibility, and consistency they need in today’s demanding clinical development environment,” noted Michael Soenen, managing partner of ClearTrial. “Our customers are saving time and money on their clinical studies, while maintaining the quality of their study results. And new customers are amazed by the minimal startup effort, since they can become fully operational on the software in just a few days.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.